Medigene AG (http://www.medigene.de) (FSE: MDG1, Prime Standard, TecDAX) announced today that it has granted an exclusive, worldwide license for the development and commercialization of its preclinical stage adeno-associated virus like particles (AAVLPs) technology to the Swedish biotech company 2A Pharma AB, located in Malmö, Sweden. Under the terms of the agreement, Medigene is eligible to receive clinical, regulatory and commercial milestone payments in addition to royalties on net sales of future AAVLP products by 2A Pharma AB. Further financial details were not disclosed.
{iframe}http://www.finanznachrichten.de/nachrichten-2016-12/39494175-medigene-ag-medigene-announces-outlicensing-of-aavlp-technology-399.htm{/iframe}